Should lean people take a GLP-1? An obesity doctor's answer surprised him.

Dr. Spencer Nadolsky has prescribed GLP-1s to thousands of patients with obesity. Then a friend said most adults should take tirzepatide even if they aren't overweight.

Should Everyone Take Tirzepatide? (Obesity Doctor Reacts to Mike Israetel)

Dr. Mike Israetel is not subtle. The famous fitness YouTuber posted this on Instagram: 'My wacky but evidence-based opinion. Most adults should consider taking tirzepatide, even if they aren't overweight. Its non-weight mediated health benefits are massive. Most people will be healthier on it than off of it.'

Spencer Nadolsky is an obesity doctor. He has prescribed GLP-1s to thousands of people. He calls himself a GLP-1 shill. And his first instinct was to pick the statement apart.

The biggest problem, he says, is not the claim. It is the two words 'evidence-based' sitting next to 'even if they aren't overweight.' Because when it comes to lean people taking tirzepatide, we are in what he calls an evidence-free zone.

Had he removed that part about not being overweight, this actually could be considered an evidence-based statement.Dr. Spencer Nadolsky

What the trials actually studied

Every major phase three trial of tirzepatide, the one that became Mounjaro and Zepbound, looked at one of two groups. People with type 2 diabetes. Or people with overweight or obesity.

We know the drug works in those populations. We have randomized trials showing massive health improvements. What we do not know is whether people at a normal weight who are otherwise healthy get any meaningful benefit.

And that matters, Nadolsky says, because the risk is not zero. GLP-1s have side effects. They are relatively rare and relatively low. But if there is no proven benefit in lean healthy people, then even rare risks start to outweigh unknown or nonexistent gains.

Had Israetel said 'my wacky hypothesis,' Nadolsky says, fine. That is reasonable. But the moment you add 'evidence-based' to a claim about a population we have not studied, you are making a leap the data does not support.

Then he changed his mind

Nadolsky is a fan of what is called the steel man argument. You take the strongest, most charitable version of someone's claim and argue from there. The opposite of a straw man, where you misrepresent what they said.

So he steel manned it. And he realized Israetel said 'most adults,' not 'all adults.' That is a different claim.

Most adults in the United States have overweight or obesity. That is the majority right there. But there is another group. People who look lean, whose BMI is normal, but who are actually experiencing harm from excess body fat. Nadolsky calls this clinical obesity.

You can have a BMI under 25, no visible belly, and still have metabolic dysfunction, fatty liver, insulin resistance. The kind of damage we associate with obesity, happening in someone who does not look overweight.

If you add those people to the overweight and obese population, you start approaching 'most adults.' And suddenly the claim starts to make sense.

Somebody could have a normal BMI and look like they don't have much body fat, but they are actually having signs of clinical obesity.Dr. Spencer Nadolsky

Why this matters if you haven’t started yet: If you are starting a GLP-1 and your BMI is under 25, ask your doctor whether you have markers of metabolic harm, like elevated liver enzymes, insulin resistance or visceral fat on imaging. That is clinical obesity, even if the scale says otherwise.

The signals no one expected

Nadolsky went further. He thinks most people will eventually be on these drugs in some form. Not now. But in a distant future. Because he is seeing benefits that have nothing to do with weight.

Early in the 2020s, when Mounjaro was still only approved for type 2 diabetes, Nadolsky was prescribing it off-label for obesity. Right away, patients with alcohol issues told him they had stopped craving it. Some stopped drinking entirely.

He posted about it on TikTok. The video went viral. Thousands of people said they noticed the same thing. He went back through his clinic data and found a signal. Now there are randomized trials underway. One trial of low-dose semaglutide has already shown some benefit.

Plenty of people with alcohol use disorder do not have overweight or obesity. If tirzepatide works for them, that is a non-weight benefit in a lean population.

Right away, my patients who had potential alcohol use issues were saying they were not craving or even at all wanting any more alcohol. It was bizarre.Dr. Spencer Nadolsky

Binge eating, PCOS, and pain that disappeared

Nadolsky says tirzepatide is more powerful for binge eating disorder than any of the FDA-approved drugs: SSRIs, Topamax, Vyvanse. Studies are ongoing. Most include people with obesity. But he expects trials in people without obesity will show benefit at lower doses.

Then there is PCOS, polycystic ovarian syndrome. Most people associate it with obesity, but there is a lean PCOS phenotype. Women with normal weight, irregular cycles, insulin resistance, high androgens. Nadolsky is seeing patients with PCOS who have not lost a pound notice improvements in their cycles and symptoms.

He is also seeing something in autoimmune and inflammatory conditions. Rheumatoid arthritis, psoriatic arthritis, Crohn's, ulcerative colitis. Patients who were already on biologic drugs and still in pain. Then they started tirzepatide for obesity and the pain improved. Some of them had not even lost weight yet.

He looked for trials in lean people with these conditions. There are none. But he suspects, if they ran them, they would see benefit independent of weight loss.

I have lots of anecdotes about patients taking their biologics for these various inflammatory disorders and then the only improvement that they got was when they started tirzepatide.Dr. Spencer Nadolsky

Heart attacks, and the prevention question

The last frontier, Nadolsky thinks, is cardiovascular disease. We already know GLP-1s reduce heart attacks in people with type 2 diabetes and obesity. The next step is lean people at high risk.

He thinks tirzepatide will be used for secondary prevention, meaning you already had a heart attack and you are trying to prevent the second one. But also primary prevention. Stopping the first heart attack in someone who is lean but has a strong family history, high cholesterol, or other risk factors.

That is where he thinks the future is heading. Not treating disease. Preventing it.

Let's say you have a normal BMI now. But your parents both developed type 2 diabetes in midlife. Your weight is creeping up despite what you eat and how much you move. Should a doctor wait until you hit a BMI of 30 and develop complications? Or should they give you a small dose now and stop it before it starts?

Nadolsky thinks that is the best use case. And he thinks it is coming.

Why this matters if you haven’t started yet: If you have a strong family history of obesity or type 2 diabetes and your weight is starting to climb, ask your doctor now whether early intervention makes sense. Do not wait for a diagnosis.

Why he does not take one himself

People ask Nadolsky all the time: if these drugs are so great, why aren't you on one?

He does not have an indication. He is lean and active. He has food noise. He thinks about shawarma and chips constantly. He has Hashimoto's thyroiditis, an autoimmune condition, so maybe there would be some benefit. But right now, he says, there is no evidence to support it.

Could he see himself taking one in the distant future, if data shows it prevents heart attacks in lean healthy people? Yes. But not now.

He does not think we should be recommending tirzepatide to most people yet. But he does see a future where that becomes evidence-based. The key word is 'yet.'

I don't have an indication. Is it possible that I take one in the near future? Probably not the near future, but I see a distant future if we get some more data.Dr. Spencer Nadolsky

The problem with dosing in lean people

Even if you are lean and want to try tirzepatide for one of these off-label reasons, there is a practical problem. If you do not have excess body fat, you would need a much smaller dose than what is used for obesity.

People call them micro doses. Sub-therapeutic doses. And we do not know if those doses deliver the same benefits Nadolsky is seeing in his patients with obesity who are on 5 mg, 10 mg, 15 mg.

That is exactly why, he says, we need data and caution. Not hype. Not exaggeration. We need trials in lean populations at lower doses before we can call this evidence-based.

Nadolsky does not prescribe tirzepatide to people who do not have a proper indication. But he has a lot of patients with overweight or obesity who also have binge eating disorder, PCOS, autoimmune conditions, or alcohol cravings. And for them, he is absolutely using it.

The question is not whether GLP-1s will eventually be used in lean people. Nadolsky thinks they will. The question is whether we are there yet. And his answer, for now, is no. Not until the evidence catches up to the hypothesis. Not until we know the benefit outweighs the risk. Not until someone runs the trial in the people Israetel is talking about and publishes the results. Then, he says, we can call it evidence-based. Until then, it is just wacky.

Questions people ask

Can you take tirzepatide if you are not overweight?

Tirzepatide has only been studied in people with obesity, overweight, or type 2 diabetes. There is no evidence yet that it benefits lean healthy people, and even rare risks may outweigh unknown benefits in that group.

Does tirzepatide help with alcohol cravings?

Some patients report reduced or eliminated alcohol cravings on tirzepatide, and early randomized trials of low-dose semaglutide show some benefit for alcohol use disorder. Larger trials are ongoing.

What is clinical obesity in someone with a normal BMI?

Clinical obesity means you are experiencing harm from excess body fat, like insulin resistance or fatty liver, even if your BMI is under 25 and you do not look overweight. It is sometimes called metabolically unhealthy normal weight.

DS
Dr. Spencer Nadolsky

Dr. Spencer Nadolsky is a triple board-certified obesity specialist who has overseen thousands of patients on GLP-1 medications at clinics across the United States. 91,569 views on the original video.

Watch the original on YouTube →

Trending Topics

Free, from GLP‑1 Classified

Thinking about a GLP‑1? Read our guide before you start.

The questions to ask, the costs nobody mentions, and what the first month really feels like. Plus a short weekly letter for people on, or considering, a GLP‑1. We are not a pharmacy or a telehealth brand. We work for you, not for them.

No spam. Unsubscribe any time.